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Background: Postpartum hemorrhage (PPH) is the leading cause of maternal mortality in developing countries.
While incidence of PPH can be dramatically reduced by uterotonic use immediately following birth (UUIFB) in both
community and facility settings, national coverage estimates are rare. Most national health systems have no
indicator to track this, and community-based measurements are even more scarce. To fill this information gap, a
methodology for estimating national coverage for UUIFB was developed and piloted in four settings.
Methods: The rapid estimation methodology consisted of convening a group of national technical experts and
using the Delphi method to come to consensus on key data elements that were applied to a simple algorithm,
generating a non-precise national estimate of coverage of UUIFB. Data elements needed for the calculation were
the distribution of births by location and estimates of UUIFB in each of those settings, adjusted to take account of
stockout rates and potency of uterotonics. This exercise was conducted in 2013 in Mozambique, Tanzania, the state
of Jharkhand in India, and Yemen.
Results: Available data showed that deliveries in public health facilities account for approximately half of births in
Mozambique and Tanzania, 16% in Jharkhand and 24% of births in Yemen. Significant proportions of births occur in
private facilities in Jharkhand and faith-based facilities in Tanzania. Estimated uterotonic use for facility births ranged
from 70 to 100%. Uterotonics are not used routinely for PPH prevention at home births in any of the settings.
National UUIFB coverage estimates of all births were 43% in Mozambique, 40% in Tanzania, 44% in Jharkhand,
and 14% in Yemen.
Conclusion: This methodology for estimating coverage of UUIFB was found to be feasible and acceptable. While
the exercise produces imprecise estimates whose validity cannot be assessed objectively in the absence of a gold
standard estimate, stakeholders felt they were accurate enough to be actionable. The exercise highlighted
information and practice gaps and promoted discussion on ways to improve UUIFB measurement and coverage,
particularly of home births. Further follow up is needed to verify actions taken. The methodology produces useful
data to help accelerate efforts to reduce maternal mortality.
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Globally, the number of maternal deaths has significantly
declined, from an estimated 376,034 in 1990 to 292, 982
in 2013 [1]. The rates of change however are not sufficient
to achieve a reduction in maternal mortality ratio by
three-quarters by 2015 [1]. To accelerate the decline in
countries where the largest numbers of deaths occur, the
major causes of maternal mortality need to be addressed.
Postpartum hemorrhage (PPH) is the leading cause in
developing countries, and contributes nearly 20% of
maternal deaths globally [2].
For the prevention of PPH, a uterotonic should be
given to all women in the third stage of labor (i.e.,
immediately after birth), preferably oxytocin [3]. Prophy-
lactic uterotonic use remains the most effective of the
three components of active management of the third stage
of labor (AMTSL). About 38% of women in developing
countries who do not deliver with a skilled birth attendant
[4] are not offered oxytocin or AMTSL. Misoprostol is an
alternative uterotonic, and it has been used safely for PPH
prevention at home births [5].
Numerous countries and development agencies have
committed substantial resources to improving the cover-
age and quality of uterotonic use for PPH prevention,
but lack a widely reported standardized indicator to
monitor the use of prophylactic uterotonics. Current
priority maternal health indicators [6] focus on contacts
with the health system (e.g., percentage of births with a
skilled attendant), but do not measure the content of
care provided. The World Health Organization there-
fore recommends that a content-based indicator be
used, defined as the percentage of women that receive a
prophylactic uterotonic drug after birth among all
women giving birth. Currently, data on prophylactic
uterotonic use for all women giving birth are scarce. A
2012 survey conducted by the Maternal and Child
Health Integrated Program found that only 15 of 37
USAID MNCH priority countries had an indicator for
AMTSL and not all of these reported it to the national
level [7]. None reported uterotonic coverage for women
delivering at home.
To be able to measure this new content-based indicator
for this key practice and track progress over time on
prophylactic uterotonic use for all births, an exercise
was developed to help national experts and stakeholders
estimate national population-level coverage. For the pur-
poses of this paper, this indicator is referred to “uterotonic
use immediately after birth (UUIFB)” and is defined as
10 IU IM oxytocin or 600 mcg of misoprostol PO, given
in the third stage of labor at any birth (i.e., at home or in a
health facility). This article reports the UUIFB estimates
derived from the exercise conducted in four settings:
Mozambique, Tanzania, the state of Jharkhand, India, and
Yemen.Methods
Development of the methodology
A landscape analysis was conducted in mid-2012 to
identify current and potential methods of estimating
UUIFB nationally. Key findings were the scarcity of data
on UUIFB and the need to improve estimation of this
key intervention. Table 1 presents six possible methods
for UUIFB estimation, roughly ranked for validity (i.e.,
accuracy). Generally, the methods that produce the most
valid information are the more expensive and time-
consuming to conduct. All methods are exclusively or
mainly focused on facility-based deliveries and are un-
likely to capture UUIFB at home births.
In December 2012 MCHIP presented the results of the
landscape analysis to group of 19 experts and researchers
working in international maternal health programs. The
global expert panel confirmed the value of the process
given that such estimates are not currently available. It
reviewed possible methods of estimation (Table 1) and
recommended as a rapid estimation exercise combining
several methods to balance validity with feasibility consid-
erations. First, the best available data from all available
sources (i.e., the results of all methods encompassed by
Methods 1–5 in Table 1) would be collected and evaluated
for data quality by an in-country facilitator, preferably
someone with a strong research background. Next, the
Ministry of Health (MOH) would convene a panel of
15–20 experts with in-depth knowledge and experience
with maternal health measurement and practice, such as
senior MOH officials, researchers, representatives from
technical organizations (e.g., WHO, UNICEF, donors,
international and national non-governmental organi-
zations) and leaders from professional associations.
The panel would be surveyed (i.e., an example of
Method 6 in Table 1) and then invited to a meeting to
review the gathered information and use the algorithm
described below to generate a national estimate of UUIFB
coverage.
The algorithm used three data elements focusing on
coverage in all birth locations, weighted by the percent
of women giving birth in each of those locations. Infor-
mation was gathered from publically available health
management information systems (HMIS) or surveys
or program data. When such data were not available,
estimates were derived through panel deliberation and
consensus based on the experience of the panel members
themselves:
1. Distribution of birth locations
○ Proportion of facility-based births by sector:
public, private, and non-governmental
organization (NGO). Further stratification by
health facility level if deemed relevant to the
calculation by the panel (e.g. significantly
Table 1 Possible methods for estimating national UUIFB coverage
Method (ranked by validity) Feasibility and validity considerations Example
1 Observational assessments of quality
of care
● Most accurate information for those births observed Done in MCHIP Quality of Care assessments
and now included as an optional Demographic
and health Survey (DHS) Service Provision
Assessment (SPA) module (done in Kenya;
planned for Malawi)
● Not commonly done
● Expensive to conduct
● When done, not likely to be on a large and nationally
representative sample
● Likely excludes home births
2 Facility readiness assessments ● Need to extrapolate from availability of commodity/
personnel to actual use of uterotonic
DHS SPA, Service Availability and Readiness
Assessment (World Health Organization)
● Expensive to conduct on a representative sample on
a regular basis
● Likely excludes home births
3 Routine Health Management
Information System (HMIS) data
● Only possible where data are recorded in registers and
reported to higher levels
Included in registers in some countries
(e.g., Mozambique)
● HMIS data quality variable
● No additional data collection costs required
● May not include community-level reporting on home
births
4 Data from sentinel surveillance sites ● Only possible where such sites are available MCHIP used this method in Kenya
(results unpublished)
● No additional data collection costs required
● Question of generalizability
5 Extrapolation from service contact
data
● Estimates require extrapolation with questionable
assumptions (i.e., that skilled birth attendant and/or
institutional birth implies use of uterotonic in most
or all of covered births).
Suggested method – expert panel not
aware of previous experience with this
● No additional data collection costs required
6 Survey of key informants ● Easy and low cost to interview individuals or group
of informants
Suggested method – expert panel not
aware of previous experience with this.
● Likely to be subjective with opinions likely biased
and/or based on incomplete information
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compared to health centers).
○ Proportion of home births, disaggregated by
attendance of a skilled provider
2. Measurements or estimates for the coverage of
UUIFB using a recommended uterotonic (i.e.,
oxytocin, ergometrine or misoprostol) in each
identified birth location.
3. Adjustments to those initial measurements or
estimates of UUIFB, considering additional
information on frequency of stockouts and
uterotonic quality.
The group also considered supporting qualitative in-
formation derived from relevant documents, including
national policies on uterotonic use, providers authorized
to use uterotonics, presence of uterotonics on the List of
Essential Medicines.
The quantitative information was utilized to con-
struct a four-term equation applied to each relevantbirth location and then summed over all those birth
locations:
UUIFBnational ¼ Σ Pa  Esta  SIa Qað Þ
þ Pb  Estb  SIb Qbð Þ
þ… Pz  Estz  SIz Qzð Þ
Where:
UUIFBnational is the national estimate of UUIFB
coverage
Pa is the proportion of births in Location A (e.g.,
home, public facility, etc.)
Esta is the initial estimate of UUIFB coverage in
Location A
SIa is the “stock-in” rate of uterotonic in Location A
(i.e., commodity availability or 100% minus the stock-out
rate)
Qa , an optional factor, is the estimated quality (i.e.,
biological potency) of the uterotonic in Location A
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identified birth locations (i.e., Locations A to Z).
Country selection
Four settings were purposively selected. The settings,
which cover a variety of geography and contexts, had
MOH interest and were programmatically important
because of large numbers of maternal deaths. Maternal
mortality ratio estimates in the four settings are high
(i.e., 270–480 per 100,000 live births) [8]. A single
Indian state was selected because of the heterogeneity
of health service delivery across India and the fact
that authority is decentralized to states for health
programs.
Implementation of the estimation exercise
General description and preparation
The exercises were conducted in Mozambique, Tanzania
and Jharkhand, India between April and July 2013
and in Yemen December 2013. The approach was the
Modified Delphi method [9-11] led by a small group
of in-country facilitators to help the expert group
reach a consensus on the national coverage estimate.
First, before convening the expert group, background
information was collected and reviewed on location
of births, policies and guidelines related to uterotonic
use, the national List of Essential Medicines, peer-
reviewed literature and program reports on availabil-
ity of uterotonics, and any other information relevant
to UUIFB coverage estimates. Supplemental informa-
tion on providers sanctioned to provide uterotonics
following birth, types of uterotonics in use, and the
existence and coverage of community-based misopros-
tol distribution for home births also were gathered.
HMIS reports, Demographic and Health Surveys (DHS),
and/or Multiple Indicator Cluster Survey (MICS) re-
ports, peer-reviewed literature, health facility assess-
ments and other relevant documents were collected and
reviewed.
A national expert panel of 15 to 30 professionals was
called to a one-day meeting. The panel composition
varied between countries, but was always comprised a
diverse set of experts that included MOH officials
working on maternal and newborn health services, se-
nior members of national professional associations,
representatives from private sector associations, key
maternal health academics and researchers, experts in
commodity supplies, facility-based service providers,
and stakeholders familiar with prevailing practices during
home birth (see Table 2). Before the exercise, participants
were sent a brief survey to gather key information on de-
livery locations, national policies, guidelines and practices.
The consultation with the expert panel was a facilitated
three step process, described below.Step 1
The expert panel first reviewed available evidence on the
location of births in the country from the most recent
DHS. Because no DHS had been conducted in Jharkhand
or Yemen, a similar population-based survey was used for
these estimates [12,13]. The group then reviewed HMIS
data for further stratification by level of service delivery
(i.e., births at regional hospitals or lower level health fa-
cilities) if it was deemed relevant to UUIFB provision.
Step 2
Beginning with data sources considered most valid and
representative (as described in Table 1), the panel then
discussed initial estimates of UUIFB in each birth
location identified in Step 1. The panel considered all
available data, which had been gathered by the facilita-
tor in consultation with panel members. The data
sources ranged from observational studies of quality
(Mozambique and Tanzania for public facilities), to
HMIS data (all but Yemen), to opinion of the panel
members when no other data source was available, as
was usually the case for non-public sector facilities.
Variations on measurements around timing of the
provision of uterotonic reported in the available data
sources (e.g., within one versus three minutes after
birth) were discussed, and a consensus decision was
made about which measurements would be used on a
country-by-country basis.
Step 3
Finally, the panel considered factors that might require
adjustment of the initial estimates of UUIFB in each
birth location, such as stock-out rates and reports on
drug quality or potency. The modifying factors were
used to adjust the initial estimate. The qualitative infor-
mation (i.e., on providers authorized to use uterotonics,
policies, and presence of the uterotonics on the List of
Essential Medicines) was used as a check on the likely
accuracy of quantitative estimates.
Final calculation and recommendations
Table 3 summarizes all the data sources used for the cal-
culation. The calculation of the UUIFB value was done by
the expert panel, facilitated by use of a spreadsheet that
calculated the weighted average. Upper and lower bounds
on the estimate then were assigned based on a consensus
view of the uncertainty of various data elements included
in the calculation. Panel members discussed key gaps in
information, likely causes of lower than expected coverage
and recommendations for improving UUIFB coverage and
its estimation.
MCHIP also reconvened the global expert panel in
July 2013 to review the methodology in light of results
from the initial three exercises.



















Mozambique 1 1 7 2 2 1 14
Tanzania 0 4 10 4 2 0 20
Jharkhand, India 6 3 12 1 4 5 31
Yemen 1 3 6 2 7 3 22
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No IRB approval was required because it was not human
subjects research, gathered no primary data, and used
only publically available data.
Results
Estimates of distribution of births by location
Figure 1 presents the distribution of births by delivery
location in the four settings, generated by the expert
panels [14,15]. In Tanzania and Mozambique, home
births account for close to half of all deliveries (48.1 and
45.2%, respectively), while in Jharkhand they account
for 62.0%, and 76.0% in Yemen. Facility-based deliveries
in public hospitals and health centers account for 54.6%
of births in Mozambique, 41.0% in Tanzania, and 16.0%
in Jharkhand. In the case of Mozambique, facility deliv-
eries outside the public sector were negligible (0.2%),
but in other settings, a substantial fraction of births
occur outside the public sector, as in Jharkhand (20.8%
in private; 0.8% in faith-based NGO) and Tanzania
(7.5% in faith-based NGO facilities). Data from public
and private facilities are combined in Yemen.
Because of known differences in coverage of UUIFB in
different levels of public health facilities in some settings
and for births attended by skilled birth attendants
(versus non-skilled attendants), some refinements
were applied to the estimates of distribution of birth
locations and these are shown in Figure 1. In Tanzania,
public facility births were further stratified by level (health
center versus hospital). A small fraction of home births
are attended by a skilled birth attendant (SBA) in three of
the settings (Tanzania, Yemen and Jharkhand); and a small
percentage (0.2%) of facility-based deliveries in public
facilities are conducted by non-qualified personnel in
Jharkhand.
Initial UUIFB coverage estimates by delivery location
All available information was reviewed and discussed
to arrive at UUIFB coverage for each identified delivery
location. Data from facility-based assessments were
used where available, complemented by HMIS data. In
Yemen, no specific data on UUIFB in any location were
available, so the expert panel made estimates, based on
its consensus opinion.For facility-based birth locations, initial UUIFB coverage
estimates ranged from a low of 70% in public facilities
in Yemen to as high as 100% for private facility births
in Jharkhand and Mozambique. In Mozambique and
Tanzania, recent observational assessments of the quality
of labor and delivery care had been conducted, from
which the panel was able to draw facility-based UUIFB
provision [16,17]. Based on these data the Tanzanian panel
estimated UUIFB coverage in most public and private fa-
cilities to be 81.5%, averaging findings from health centers
(71%) and central hospitals (99%). The Mozambique panel
took the national HMIS reported uterotonic use (94%),
and revised this figure downward based observational as-
sessment finding that uterotonic use within three minutes
of birth (i.e., an even more stringent standard than UUIFB
implies) was 68%. In Yemen, UUIFB coverage was esti-
mated to be 70% for facility deliveries. In Jharkhand
UUIFB coverage was estimated to be 90% for all public
and private facilities.
For home births, little information on UUIFB coverage
was available. In Jharkhand approximately 15% of deliver-
ies occur at home with an SBA, and the panel’s consensus
opinion was that UUIFB coverage in this setting was ap-
proximately 85%. Taking into account the distribution of
births and UUIFB in this delivery location, UUIFB cover-
age for home births attended by an SBA contributed
29.8% of total UUIFB coverage in Jharkhand and 42.9% in
Yemen, but in Tanzania it contributed only 2.0% and in
Mozambique 0%. In all settings, home-based deliveries
without an SBA were estimated as having 0% UUIFB
coverage. This reflected the absence of home-based utero-
tonic provision programs, such as distribution of miso-
prostol for non-SBA attended home births.
Adjustments to initial coverage estimates by birth location
Stockouts of uterotonic were a key modifier applied to
the original coverage estimate.
Estimated stockouts of uterotonic for Jharkhand ranged
from 0-33%, with the opinion of the panel that stockouts
were more frequent at more peripheral facilities. Stock-
outs at all facilities in Tanzania were estimated at 2%,
taking facility audit findings into consideration. In
Mozambique, a 2011 national UNFPA commodity avail-
ability assessment showed a nationwide stockout rate of
Table 3 Data sources used for parameters needed to estimate UUIFB coverage
Mozambique Tanzania Jharkhand Yemen
% Births in location (P) Mozambique National Statistics Institute
and ICF International. 2011. Mozambique
Demographic and Health Survey.
Calverton, MD, USA
National Bureau of Statistics (NBS)
[Tanzania] and ICF Macro. 2011.
Tanzania Demographic and Health
Survey 2010. Dar es Salaam,
Tanzania: NBS and ICF Macro.
Vital Statistics Division, Office of
the Registrar General & Census
Commissioner, Government of
India: Annual Health Survey
2010–11 Fact Sheet Jharkhand.
New Delhi, 2012.
Ministry of Planning and International
Cooperation, Republic of Yemen:
National Social Protection Monitoring
Survey of Yemen: Baseline Analytical
Report June 2013. Brasilia, 2013.
% UUIFB in location (Est) Public facilities: Mozambique Ministry of
Health and MCHIP. 2011. Quality and
Humanization of Care Assessment: A
Study of the Quality of Maternal and
Newborn Care Delivered in Mozambique’s
Model Maternities. Accessed April2013:
http://www.mchip.net/node/1847.
Public facilities: MCHIP: Quality of
Care for Prevention and Management
of Common Maternal and Newborn
Complications: A study of 12 regions
in Tanzania. Report 2: Findings on






Consensus opinion of Expert
Panel, based on direct
experience as clinicians
and managers in each of
the settings.
Consensus opinion of Expert Panel,
based on direct experience as
clinicians and managers in each
of the settings.
% stock-in (SI) Public facilities: Ministry of Health, Republic
of Mozambique and UNFPA: Second Survey
of Availability of Modern Contraceptives and
Essential Lifesaving Maternal/Reproductive
Health Medicines in Service Delivery Points.
Report of Mozambique 2011. Maputo, 2012
All facilities: Stanton C, Armbruster D,
Knight R, Ariawan I, Gbangbade S,
Getachew A, Portillo JA, Jarquin D,
Marin F, Mfinanga S, Vallecillo J,
Johnson H, Sintasath D: Use of active
management of the third stage of
labour in seven developing countries.
Bull World Health Organ. 2009 Mar;
87(3):207–15.
Consensus opinion of Expert
Panel, based on direct
experience as clinicians
and managers in each of
the settings.
Consensus opinion of Expert Panel,
based on direct experience as
clinicians and managers in each
of the settings.











































Home births: with SBA
Home Births: without an
SBA
*
Figure 1 Estimates of distribution of births by location in each setting. Dark red represents Home births without a skilled birth attendant
(SBA); pink represents Home births with a skilled birth attendant; green represents births in public hospitals and health facilities; purple represents
births in private health facilities; blue represents other health facilities; orange represents missing data.
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and private [18]. The expert panel in Yemen calculated
a uterotonic access rate, which factored in stockouts as
well as other supply/access issues, for SBAs at home
births at 90% and 50% for facility births. This is shown
in Table 4.
The Jharkhand expert panel incorporated an assump-
tion that 40% of oxytocin samples were not potent be-
cause of poor storage, based on findings from a recent
assessment at health facilities and took this into account
in their estimation of the effective coverage rate of qual-
ity uterotonic. This adjustment was not done in the
other three settings. The final estimates of coverage of
UUIFB among all births were 15% in Yemen, 40% in
Tanzania, 43% in Mozambique, and 44% (unadjusted) or
32% (quality adjusted) in Jharkhand. Figure 2 presents
the contributions from each setting to the national
coverage estimate and Table 4 summarizes the data ele-
ments used for calculation of UUIFB in the four settings.
Table 5 presents the key recommendations and actionable
outcomes from each exercise.
Discussion
This new methodology was effective in generating a
national-level estimate of UUIFB coverage in all four
settings and therefore filled the need for a content-based
PPH-related indicator within national safe motherhood
programs. Although there currently is no way to validate
the findings, the exercise produced results that were
acceptable to the expert panel. It provided the MOH
with measurement for monitoring and planning, as well as
actionable information to address gaps in data collection,
data quality and service provision.PPH remains the leading cause of maternal death in
most developing countries. AMTSL substantially reduces
the incidence of severe PPH [19], and more recent evi-
dence concludes that use of a uterotonic is the most ef-
fective component of AMTSL [20,21]. AMTSL has been
widely promoted in skilled attendance at birth particularly
at health facilities. At the same time, at least 19 countries
have introduced or expanded distribution of misoprostol
as a PPH prevention strategy at home births [22]. National
safe motherhood programs, however, do not have data on
national UUIFB coverage for all births to inform planning
and evaluation because data on this intervention are not
easily measured on a population basis. Health facility
readiness assessments done on a nationally representative
sample of facilities (e.g., Service Provision Assessments,
Service Availability and Readiness Assessments, and the
Averting Maternal Death and Disability assessments) are
conducted occasionally and typically measure inputs (such
as the availability of uterotonics) and not actual practice.
Facility assessments using observation of labor and deliv-
ery practices produce the most valid data, but are even
less commonly done, especially on a nationally representa-
tive sample of facilities. One such observational assess-
ment, conducted mainly in district and referral hospitals
in seven countries in Asia, Africa and Latin America from
2005–2006, found that almost all (98–100%) women re-
ceived a uterotonic during the third or fourth stage of
labor [23]. Few national HMIS currently record and report
data on AMTSL or UUIFB. Data from all three of these
sources often are limited to public sector facilities and do
not take account of the substantial proportion of women
who give birth at home. Population-based surveys such as
DHS and MICS rely on self-reported data and therefore
Table 4 Calculation of UUIFB coverage estimates for Mozambique, Tanzania, Jharkhand (India), and Yemen
Mozambique Tanzania Jharkhand Yemen














































45.2% 0% ─ 0.0% 47.0% 0% ─ 0.0% 46.7% 0% ─ 0 66.0% 0.0% ─ 0.0%
Home births: with SBA ─ ─ ─ ─ 1.1% 70% N/A 0.8% 15.3% 85% 100% 1 % 10.0% 70.0% 90.0%e 6.3%
Public facilities 54.6%a 80% (62-94%) 97.5% 42.6% 41.0% 71%f 98% 30.9% (28.7-32.8%) 16.0%c 90% 67-93%d 1 % 24.0% 70.0%b 50.0%e 8.4%b
81.5%f
99%f
Private facilities 0.2% 100% 100% 0.2% 1.6% 81.5% (80-83%) 98% 1.3% (1.2-1.3%) 20.8% 90% 100% 1 % ─ ─ ─ ─
Other facilities
(Faith-based, NGO)
─ ─ ─ ─ 7.5% 81.5% (80-83%) 98% 6.0% (5.9-6.1%) 0.8% N/A N/A N ─ ─ ─ ─
Missing data ─ ─ ─ ─ 1.8% – N/A 1.3% 0.4% ─ ─ ─ ─ ─ ─ ─
National UUIFB
coverage estimate
100.0% 43% (34–49%) 100.0% 40% (37–42%) 100.0% 4 100.0% 15%
N/A not available, ─ not applicable.
aSince there are not separate coverage or stockout data for Hospitals and Health Centers, the two are reported together.
bData from Yemen combines public and private facility delivery data.
cThe expert panel in Jharkhand had disaggregated facility deliveries by SBA (15.8%) and non-SBA (0.2%).
dThe expert panel in Jharkhand had disaggregated facility deliveries by three types of health facilities and attributed different stock-in rates for each, therefore a nge is presented and relative stock-in rates reflected
in the calculation of state coverage.
eThe expert panel in Yemen calculated a uterotonic access rate which considered stock in facilities, availability in outside pharmacies, ability to pay and frequenc with which facilities provide it to women who cannot
afford to purchase the drugs outside.























































































Figure 2 Final consensus estimate of total UUIFB coverage. Dark red represents Home births without a skilled birth attendant (SBA); pink
represents home births with a skilled birth attendant; green represents births in public hospitals and health facilities; purple represents births in
private health facilities; blue represents other health facilities; orange represents missing data.
Table 5 Recommendations by the expert panel from the UUIFB estimation exercise in each setting
Setting Key recommendations
Jharkhand, India ● Promote awareness among women and families about the potential and correct use of misoprostol for prevention of PPH.
● Develop a program for the advanced distribution of misoprostol to women who deliver at home.
● Improve commodity management to reduce the rate of stock-outs of uterotonic drugs.
● Further understand and improve the quality of oxytocin.
● Improve data gathering and data quality for UUIFB.
Mozambique ● Improve UUIFB coverage in the public sector through quality improvement measures.
● Expand the use of misoprostol in the community. Just expanding to the 35 planned districts this year would increase
national UUIFB coverage by more than 10%.
● Emphasize in maternity norms that oxytocin should be given within one minute of birth. The birth attendant must prepare
the dose before the birth.
● The MOH should authorize all providers who attend births to give oxytocin.
● Given its importance as a medicine, the need is urgent to investigate the potency of oxytocin.
● MCHIP could make funds available to finance the purchase of equipment to strengthen the cold chain for oxytocin.
Tanzania ● Improve data on home-based use of uterotonics.
● Improve commodity management and tracking, especially at lower level health facilities
● Track stockout of all possible approved uterotonics, rather than tracking them individually
● Improve data quality and gathering on UUIFB, including defining UUIFB for these purposes
Yemen ● Increase supply of uterotonics in facilities
● Increase knowledge of providers about uterotonic use
● Develop educational materials to clarify providers’ understanding of the benefits and uses of misoprostol
● Pilot the use of misoprostol for prevention of PPH at home birth
● Review/modify the job description of midwives to ensure permission to use misoprostol for PPH prevention
● Work with High Commission for Medications to approve the use of misoprostol for PPH prevention and treatment.
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UUIFB, as a recent study has shown that women’s recall
about the receipt of an injection immediately following
birth is very poor [24].
The uterotonic estimation exercise described in this
paper was devised to fill this information gap on UUIFB
coverage. The method is similar to that used for the
Maternal and Neonatal Program Effort Index to estimate
national programmatic effort in the reduction of maternal
and newborn death [25] and the method has also been
used to estimate the effectiveness of maternal and new-
born interventions on mortality [10,11]. Participants in
several settings stated that they felt the process was
feasible and transparent and helped them arrive at an
estimate accurate enough to be actionable. For example,
the panels identified access to uterotonics as the largest
contributor to suboptimal national UUIFB coverage. Be-
cause the methodology estimates population coverage,
it should allow Ministries of Health to be more strategic
in identifying the most potentially effective strategies to
improve UUIFB coverage for all births regardless of
delivery location, and thereby promote more equitable
uterotonic coverage.
The exercise highlighted how uterotonic availability
and quality can influence national UUIFB coverage. Yet
uterotonic availability at the facility level is not tracked
nationally in any of the four settings. In Tanzania, the
national program tracks oxytocin, ergometrine and mi-
soprostol stockouts separately, but does not identify
when facilities experience a stockout of all uterotonics
simultaneously. Degradation of injectable uterotonics
due to exposure to light and heat has been documented
[26], and recent studies of uterotonics collected from
health facilities and pharmacies in developing countries
have raised concerns about quality, particularly of
oxytocin [27-29]. A study in India found 22%-50% of
oxytocin and 44-54% of methylergometrine samples did
not meet manufacturer specifications for potency (90%-
110% active pharmaceutical ingredient) in Uttar Pradesh,
a neighboring state to Jharkhand. [Personal Communica-
tion, Nitya Nand Deepak, PATH/India] Concerns persist
as well about misoprostol deterioration due to moisture, if
not packaged properly [30]. Clearly, efforts to raise effect-
ive coverage can be blunted by inattention to pharmaceut-
ical quality. This should be taken into account as national
governments formulate strategies to raise UUIFB coverage
rates.
This exercise also highlighted the programmatic gaps
around UUIFB for home births. Although WHO recom-
mends misoprostol for PPH prevention at home births
where SBAs and oxytocin are not available [4], none of the
four settings studied in this exercise currently have a large-
scale program to ensure UUIFB for the nearly 50% of births
occurring at home. In the short term, national UUIFBcoverage in all four settings can only substantially increase
if UUIFB at home births is addressed. Evidence suggests
that community-based programs for PPH prevention at
home births using misoprostol achieve the greatest cover-
age through advance distribution by community health
agents at home visits and self-administration [22].
Because of the nature of the exercise, estimates are
dependent on the quality of data available. Issues with
data quality and gaps became evident through the exer-
cise in all four settings. An important activity of the
exercise was advocacy for improved data collection and
quality related to UUIFB, similar to experiences from
data-use workshops [31]. Dissemination of the data may
stimulate greater attention to measurement of this key
indicator and hence better future estimates. The rapidity
of the exercise allows for quick input into program plan-
ning and makes possible repeated measurements. Since
the panels developed a list of priority interventions to
improve UUIFB coverage and its measurement, these re-
peat measures could be used to track progress.
Limitations
This exercise was designed to provide for the first time
population-level estimates in a field with a notable lack
of information. To do this, the panels made educated
judgments about divergent estimates for some parame-
ters and made rough estimates of others in order to
arrive at its final national coverage figure. The data
sources that were considered by the expert panels
ranged from population-based surveys (for birth loca-
tion), to observational studies of service delivery, data
from HMIS, and self-reported provider practice. In a
few cases where no systematic information existed,
expert opinion was used. There is no gold standard
methodology for comparison. Given that there are no
estimates for comparison, the validity of the UUIFB
estimates cannot be objectively assessed. The figures
on UUIFB coverage for some birth locations were the
least precise data element with the widest possible
range. The uncertainty in the estimation of this parameter
was highlighted in those instances in which more than
one estimate was available, as these were sometimes diver-
gent. None of the exercises had data from current, nation-
ally representative studies on uterotonic use after birth,
and thus had to extrapolate findings from studies not
meant for this purpose. Expert panels also used their own
judgment in assigning weight to data of varying levels of
quality and scope, with facilitation guidance from experts
on measurement issues. Some of the major extrapolation
challenges the panels faced included measurements of the
use of different types of uterotonic separately; measure-
ments which quantified uterotonic use in a timeframe that
did not correspond exactly to the concept of UUIFB (e.g.,
one minute after birth or three minutes after birth); and
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ology should be seen as an interim step toward full inte-
gration of indicators on uterotonic coverage, both for
facility and home birth. There should be follow-up to
encourage progress programmatically and in collecting
more complete and accurate information.
Conclusions
The UUIFB coverage estimation exercise produced esti-
mated levels of coverage in all four settings that were
much lower than desired or anticipated by many panel
members. While the validity of the estimates is untested
because there is no gold standard for comparison, the
exercise fills an important gap in monitoring of maternal
health programs by measuring intervention coverage of
all births. The exercise raised awareness among national
experts of low levels of UUIFB and provided them with
information for monitoring and planning that was previ-
ously unavailable. Participants felt the process was feasible,
transparent and accurate enough to be actionable. It
highlighted critical gaps in the measurement of utero-
tonic provision. It is recommended in settings where
PPH is a significant cause of maternal mortality and
PPH prevention interventions are being implemented.
UUIFB coverage estimates can provide useful data to
help plan efforts to accelerate national and global efforts
to reduce maternal mortality. Similar estimation exercises
could be devised for other key maternal health interven-
tions for which information is also currently lacking – for
instance, use of magnesium sulfate for cases of eclampsia
and severe pre-eclampsia.
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